Trazodone: A New Antiepileptic Drug for Dravet Syndrome?

Linda Azevedo Kauppila; Isabel Amorim; Carla Bentes; Ana Rita Peralta

doi:10.1055/s-0039-1677783

International Journal of Epilepsy, Table of Contents

CC BY-NC-ND 4.0 · International Journal of Epilepsy 2018; 05(02): 099-103
DOI: 10.1055/s-0039-1677783

Case Report

Indian Epilepsy Society

Trazodone: A New Antiepileptic Drug for Dravet Syndrome?

Linda Azevedo Kauppila

¹Division of Neurology, Department of Neurosciences and Mental Health, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisboa, Portugal

,

Isabel Amorim

¹Division of Neurology, Department of Neurosciences and Mental Health, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisboa, Portugal

,

Carla Bentes

²Electroencephalography and Sleep Laboratory, Neurology Division, Department of Neurosciences and Mental Health, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisboa, Portugal

³Clinical Neurology Division, Faculty of Medicine of the University of Lisbon, Lisboa, Portugal

,

Ana Rita Peralta

²Electroencephalography and Sleep Laboratory, Neurology Division, Department of Neurosciences and Mental Health, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisboa, Portugal

³Clinical Neurology Division, Faculty of Medicine of the University of Lisbon, Lisboa, Portugal

› Author Affiliations

Abstract

Dravet syndrome (DS) is associated with severely refractory seizures. Recent studies suggest possible antiepileptic effects of serotonergic drugs. We report the case of a 25-year-old woman with DS-related epilepsy (SCN1A mutation), with daily seizures since childhood, associated with developmental delay. Several antiepileptic drug regimens were tested, without clear benefit. Over the years, she maintained a pattern of diurnal and nocturnal seizures, with a nocturnal predominance averaging two tonic–clonic seizures per night, with periods of seizure clusters. On routine electroencephalography (EEG), frequent, subtle myoclonic seizures during sleep were detected. A seizure-free period or significant reduction in seizure frequency was never attained. Trazodone was started due to insomnia. This led to a remarkable as well as long-standing clinical and neurophysiological improvement: less than one reported tonic–clonic seizure per month during the next 18 months, reduction in interictal epileptiform activity (170/h vs. 30/h of sleep), myoclonic seizures (90/h vs. 0.7/h of sleep), and tonic–clonic seizures (2/night to 0) on video-EEG. Serotonergic pathway modulation effects on DS-related epilepsy were observed in animal studies, in addition to small case series using lorcaserin and fenfluramine. To the best of our knowledge, no clinical data exist showing that trazodone may be an efficacious agent in patients with DS. Despite limitation of an isolated case with possible chance factors, our data, given the striking effect, provide this clinical evidence for the first time, and may have important clinical implications in patients with DS, reinforcing the need for further research on this subject.

Keywords

Dravet syndrome - serotonergic pathways - trazodone

Full Text

References

References
1 Millichap JJ, Koh SS, Laux LC, Nordli Jr. DR. Child neurology: Dravet syndrome: when to suspect the diagnosis. Neurology 2009; 73 (13) e59-e62
2 Aras LM, Isla J, Mingorance-Le MeurA. The European patient with Dravet syndrome: results from a parent-reported survey on antiepileptic drug use in the European population with Dravet syndrome. Epilepsy Behav 2015; 44: 104-109
3 Wu YW, Sullivan J, McDaniel SS. et al. Incidence of Dravet syndrome in a US population. Pediatrics 2015; 136 (05) e1310-e1315
4 Griffin A, Hamling KR, Knupp K, Hong S, Lee LP, Baraban SC. Clemizole and modulators of serotonin signalling suppress seizures in Dravet syndrome. Brain 2017; 140 (03) 669-683
5 Aicardi J, Gastaut H. Treatment of self-induced photosensitive epilepsy with fenfluramine. N Engl J Med 1985; 313 (22) 1419
6 Ceulemans B, Boel M, Leyssens K. et al. Successful use of fenfluramine as an add-on treatment for Dravet syndrome. Epilepsia 2012; 53 (07) 1131-1139
7 Sourbron J, Schneider H, Kecskés A. et al. Serotonergic modulation as effective treatment for Dravet syndrome in a zebrafish mutant model. ACS Chem Neurosci 2016; 7 (05) 588-598
8 Ceulemans B, Schoonjans AS, Marchau F, Paelinck BP, Lagae L. Five-year extended follow-up status of 10 patients with Dravet syndrome treated with fenfluramine. Epilepsia 2016; 57 (07) e129-e134
9 Lefkowitz D, Kilgo G, Lee S. Seizures and trazodone therapy. Arch Gen Psychiatry 1985; 42 (05) 523
10 Borowicz KK, Gurdziel E, Czuczwar SJ. Trazodone reduces the anticonvulsant action of certain classical antiepileptics in the mouse maximal electroshock model. Pharmacol Rep 2012; 64 (05) 1136-1145
11 Hill T, Coupland C, Morriss R, Arthur A, Moore M, Hippisley-Cox J. Antidepressant use and risk of epilepsy and seizures in people aged 20 to 64 years: cohort study using a primary care database. BMC Psychiatry 2015; 15: 315-327
12 Morin AK, Jarvis CI, Lynch AM. Therapeutic options for sleep-maintenance and sleep-onset insomnia. Pharmacotherapy 2007; 27 (01) 89-110
13 Parrino L, Spaggiari MC, Boselli M, Di Giovanni G, Terzano MG. Clinical and polysomnographic effects of trazodone CR in chronic insomnia associated with dysthymia. Psychopharmacology (Berl) 1994; 116 (04) 389-395
14 Saletu-Zyhlarz GM, Abu-Bakr MH, Anderer P. et al. Insomnia in depression: differences in objective and subjective sleep and awakening quality to normal controls and acute effects of trazodone. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26 (02) 249-260
15 Manni R, Zambrelli E, Bellazzi R, Terzaghi M. The relationship between focal seizures and sleep: an analysis of the cyclic alternating pattern. Epilepsy Res 2005; 67 (01) (02) 73-80